Mike Bonney is a business executive with over 30 years of biotech and pharmaceutical expertise. Bonney was CEO and Director of Cubist Pharmaceuticals from 2003 until 2014. Under his leadership, Cubist grew from a struggling micro-cap to the world’s leading antibiotic company and was acquired by Merck early in 2015 for $9.5 billion. Prior to Cubist, Bonney was Vice President of Sales and Marketing at Biogen where he built the company’s commercial infrastructure for the launch of its first product. Before joining Biogen, he spent 11 years at Zeneca Pharmaceuticals in a range of commercial, operating, and strategic roles, ending his career there as National Business Director.

Bonney was a regional winner and national finalist (2013) in the life science segment of Ernst & Young’s Entrepreneur of the Year. He was one of six executives nationwide named as Marketwatch’s CEO of the Year (2011) and was named Top Performing MA CEO by Boston Business Journal in 2008.

Bonney is currently a Director of Alnylam Pharmaceuticals and Gulf of Maine Research Institute, and Chair of Dunad Therapeutics and Autolus Therapeutics. Bonney has served as a director with many companies previously including Kaleido Biosciences, Magenta Therapeutics, Bristol Myers Squibb, Sarepta Therapeutics and Syros Pharmaceuticals. Bonney spends much of his time identifying and mentoring the next generation of life science leaders. He received his undergraduate degree in economics from Bates College.